VYGR - Earnings call transcript Q4 2019 | Voyager Therapeutics, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon, and welcome to the Voyager Therapeutics Fourth Quarter and Full Year 2019 Financial Results Conference Call. At this time, all participant lines are in a listen-only mode. This call is being webcast live on the Investor and Media section of Voyager's website at voyagertherapeutics.com. This call is the property of Voyager Therapeutics and recordings, reproduction or transmission of this call without the expressed written consent of Voyager Therapeutics is strictly prohibited. Please be advised that this call is being recorded.

to Cox, like Relations of now Voyager. at would introduce Head Paul Investor I

Paul Cox

thank joining Financial President you on and and Medical afternoon Good for of Head today Officer; Khwaja, R&D; Andre Officer Executive and the Dorval, us. are Turenne, Chief our Chief and Allison Omar Chief Officer. call me With

is the which available XXXX. results and financial This market we close, the year afternoon voyagertherapeutics.com. full issued highlights at outlines fourth for after The and release a press release, quarter corporate

we just a reminder as Before in law. events XXXX. to the this March future circumstances, views reflect obligation Voyager or today by that company's update except included begin, to required forward-looking these disclaims any call statements represent of statements X, the as

release, or as the well statements. to by Please actual Voyager's risk that press expressed refer for SEC to could today's those implied with results from factors cause concerning information such materially filings differ as

over that, to With the I Andre. will turn call

Andre Turenne

Paul, we've and I'll begin session. Thank will our call. we'll and to updates. our and you through and pipeline earnings walking analyst Omar the remarks, Once plans financial update good recent QX in with programs Welcome you, guidance. Q&A Allison discuss corporate by concluded our and afternoon, our close everyone. will take results our questions

and and XXXX, toolbox on therapy. experience on therapy to this area. make gene in diseases. neurological severe to We ability we to focused gives leading gene for the enrich expertise CNS to continued build believe focus company in and continue We our innovation therapy progress to as us establish In our our gene drive that combined the Voyager neuroscience

production therapies and leveraging is the Parkinson's to of as, of therapies, believe very delivered approach advantage lead historical of disease AAV brain. regions gene delivery and has challenges We Voyager certain such that of and a were feature limited dose-limiting organs, Huntington's untargeted large distribution our important bypassing to brain the of for immunogenicity that our present this surgical key scale. systemically tissues intraparenchymal at and precise A pipeline the programs transduction, targeted disease gene potentially systemic

time, discovery invest CNS. capsids, to to deliver same of may penetrants. ability novel we've a These two that specifically continued the enhance specific sales in regions, genetic the as significantly lead the advanced broaden to variety of blood-brain we've therapies targets engineered programs, develop At barrier these in wide payloads to efforts and gene our

manufacturing Parkinson's AAV believe production at our of in AAV pipeline invest that, developed pipeline. we've the we a that production and capabilities key to manufacturing program, with and expertise Another in Voyager process enables is we continue scale. We'll our as gene feature we've leading the commercial advance therapies as shown these high-quality of

evaluated lead our the our Neurocrine, trial program updates, updated RESTORE-X to is in currently support Turning protocol also and amendments we to being the Along overall intended filing. designed program with clinical Parkinson's clinical in our in the ensuring FDA partner enhance experience VY-AADC protocol program VY-AADC after trial that disease recently trial, the The feedback. patient the while seeking receiving to is the BLA are patients.

implementing initiate in second to RESTORE-X, study plan RESTORE-X In addition global of in changes to these a half we the XXXX. to

XX-patient longer-term these data important year provide VY-AADC VY-AADC. represent on of total, to Phase will the expect also years Xb In We than program. data this data from more

an an we're IND lead the plan quarter update conducting disease, to wholly-owned for to program of provide regarding second IND-enabling preclinical application. our the VY-HTTXX currently to studies. Huntington's of plans in process this reviewing including year the Turning and We program, in file

programs vectorized of programs during the and antibody also our excited momentum We're HD other capsid prospective our to efforts initiate to middle of plan observational our We these also preclinical XXXX. on plan continue year. updates to a present study novel the and on in patients programs, efforts. We our

the Juliana Gan Voyager invest Investor for in President talent. to Vice and including Head of each just as on a Wei President on Muscat the few Cox Hunt but in Technical last gene as Development We of neurological continue focus of kicked we of of not expertise long-term to Vice recently as have Finally thrilled key We're Relations. Voyager Operations; includes therapy leadership team. made Quality; adding hires and building a Senior Jennifer President and Development; continued Vice who of Paul least; as them off call this

provide detail the over Omar? Omar program. call pipeline our With to more that turn on now to I'll

Omar Khwaja

to you, now these detail. I'd more in updates Thank program like of Andre. walk some through

partnered I'll discuss is with First Neurocrine. of which program Parkinson's the disease the updates

As a AAV deliver using vector. AADC to to gene enzyme putamen the approach the for the viral reminder is locally our an

converting infusion there The goal advantage create care putamen to enzyme exogenous to levodopa is think The dopamine. controllable a therapy reservoir an this gene a We AADC system a is volume to of standard important a of in the use onetime medication. of is to by levodopa, regulatable of the small result of oral capable stable approach.

brain are Our patient's to to titrate physicians levodopa oral individual medication need, to effects opening while or in side the systemically and able excess regions. due other avoiding patients

each is across The and designed delivery. posterior five trial three trial dosing evaluating escalating safety patients focused I was PD-XXXX of the PD-XXXX on while surgical Phase optimize studying program a doses clinical The eight using and delivery. trajectory to delivery and the using route, patients cohorts transfrontal for establish VY-AADC is

Phase to-date by motor multiple endpoints in measured we onetime I results as AADC scans study in increased replacing our across study a participants have for oral with reduced medication. activity enzyme PET of through life and significantly our quality and therapy, improvements F-Dopa observed we activity function that levodopa together see need by In the gene AADC

with results and Parkinson's we As from data and of These to sustained speak the the of of treatment patients clinical Parkinson's at effect important the progression evidence advanced the in benefit trial of mentioned, present course trial congresses predicted may of VY-AADC the PD-XXXX time from from data X-year disease. medical durability the year. context Andre at expect provide this PD-XXXX disease final X-year longer-term to both disease

data these believe the endpoints patients life of a given function disease over in decline years which at quality physician-assessed that number motor We Parkinson's multiple objective will stage disease. experience of be important, and patient-reported and of this include

worsening know experience we of example, doses patients patients dopaminergic levodopa that longer-term good such other as motor in years. alternatives after therapy studies ON of prevalent symptoms For in as stimulation three well formulations, types as or deep-brain increases declining time receiving

in randomized VY-AADC a RESTORE-X is the Phase controlled surgery study sham being double-blinded evaluated II currently trial.

treatment discussions protocol sham amendments protocol upon increase to patients implementing FDA. our approximately scheme. now plans The opposed surgery amendment or XX based the and with trial basis a the X:X are we mentioned, receive Andre prior to randomization As include to on patients as to a X:X randomized VY-AADC enrollment

expected exploratory relevant of experience participating co-modifications These act registration. to allow as RESTORE-X well-controlled enhance trial are to assessments not VY-AADC patients We're support of of two support and adequate sites and disease. one treatment of to post Parkinson's the trials to reducing also the in the and for registration

efficacy secondary changes no Importantly, there endpoints. the are primary endpoint key or to

lines We this update implementation amendment. following time expect RESTORE-X of to enrollment protocol

second of second the the pivotal expect to in also XXXX. with initiate trial RESTORE-X half We Neurocrine together of

microRNA an VY-HTTXX, down mRNA. VY-HTTXX encoding owned gene treatment a AAV now huntingtin novel to Turning our human therapy designed wholly lead program the based for of to knock is Huntington's disease.

cortex. pursuing the delivery paradigm neuronal to thalamus, extensive a both putamen We disease as VY-HTTXX thalamus' the of by both the are delivery and to projections sites novel targeted as pathology leveraging the primary local well

resulted presented in have and HTT mRNA We delivery vector VY-HTTXX previously and data genome distribution of non-human widespread VY-HTTXX both of cortex. putamen into and across and and knockdown robust of demonstrating the primates protein durable that thalamus striatum of

YACXXX to YACXXX in recently results of update provide second presented strides conduction to Conference vehicle-treated the engaged file in VY-HTTXX-treated mRNA this in significant as the of Annual an to the an CHDI that of for and the plans the VY-HTTXX protein Huntington's We're studies IND at motor Concomitant in program including function mouse animals. compared data improvements significant mice our lowering showed expect model treatment and including of mice, year, ongoing a Therapeutics significant review preclinical and quarter in transgenic application. human disease. human also well-characterized HTT with reductions, We've dose-dependent in HTT VY-HTTXX

patients will examining evaluate study planning Huntington's XX in enrollment also digital also observational clinical prodromal neuroimaging late of get they biological patients the to disease This longitudinal endpoints to study symptoms. the VY-HTTXX prospective months of of for and by premanifest study disease with clinical later and Patients participating progression program. may clinical evolution over trial disease early We're eligible mid-XXXX. in and as be in the manifest relate in biomarker Huntington's observational Huntington's molecular changes

These for preclinical AbbVie our including programs our wholly-owned antibody programs Friedreich's our Finally, of our as these include programs and novel efforts in tau alpha-synuclein initiatives of as We as to we efforts partners characterization discovery as research the development, Neurocrine. our across plan on all capsids. and collaboration with give advance program well ataxia earlier-stage continue new initiatives currently in assets well our AAV and updates to XXXX. vectorized and research

I'll to on the now call Allison. pass

Allison Dorval

highlights securities $X.X We the and in $XXX.X million revenues $X.X and cash, results and cash million the million ended at million compared XXXX. with We for position financial and $XXX.X same million booked compared of QX marketable our the review guidance. of to for the in collaboration strong end periods now debt $XXX.X financial year I'll of equivalents Omar. XXXX to XXXX. Thanks, of in a million XXXX respectively $XX.X

related to became Neurocrine our amounts to alpha-synuclein QX the This XXXX. and recognition of Sanofi related of in both of in increase Genzyme and effective June collaboration reflects amounts AbbVie the which collaboration,

$XX.X XXXX the period related million year, $XXX.X $XX.X million million QX $XX.X was $XX.X XXXX. million same QX R&D of XXXX compared expenses loss to for and for for the the were year, and the including the million $XX.X full and and trial XXXX. The costs million compared for respectively for Net pipeline for expenses increase to same programs, support respectively to of $XX.X R&D in primarily VY-AADC. for costs period to our $XX.X employee-related was advancing and RESTORE-X million external million

XXXX million QX and primarily for and and compared expenses for in same $XX.X operations. the respectively XXXX. and million increase the programs The G&A year, facility our employee to $X.X to for was million of related million were periods support to costs expenses advancement $X.X $XX.X pipeline the G&A of

guidance. financial our to now Turning

multiple securities this XXXX million. collaboration end the debt with be with Neurocrine we reimbursement cash cash established will to current operating development costs approach $XXX financial milestone disciplined million our events equivalents look sufficient and operating mid-XXXX. expect we from through forward plan, we capital XXXX. marketable balance Based needs we for and to continuing on have into and programs a partnering through our believe strategic cash, our $XXX strong expenses We and amounts expect our in that across meet position receive projected between our We expenditures and to along our for of to capital expect progress strategy

With to that, call we open like now questions. Operator? the for would

Operator

Instructions] Our Thank Chico first you. with question the comes [Operator Laura line from Wedbush. of

is now open. line Your

Laura Chico

two Hey, thanks I question. you. very much taking just for for the have

mentioning that exploratory schedule? to that of terms to a I randomization then, be little the to secondarily, more the FDA the permit you were specific Could think are looking maybe at? confidence gave I in Omar, in some amendments you what elaborate those with And change RESTORE. of filed specifically regards measurements on that going you were changes? think bit

Omar Khwaja

Thanks, Laura.

at been to the learnings of study conduct a And XX and for have So, support the was we but an that going two active. sites study approximately potentially of to the were the the will because to the of structured of as exposures given are came visits so for number conducted. incorporating which really included and the study actually number We has for two that and assessments around things. to been One proposal patients that in number or agreement plan for example with were have serve safety. was of about the the well-controlled also a FDA elements we the back operational uncomfortable reduce of And -- from year the OFF now the trials XX. number statistical state, in where active of powering to the one analysis number efficacy, things being on we this RESTORE-X a filing, patients. had increasing adequate decided exploratory These also amendment our both for then to main of participants

And number those. so, the we reduced of

neuropsychological eligibility and the exploratory in will amendment. fact the And essentially time-consuming. assessments a removed that the amendment the not scheme. the more substantially is think detailed, We a number proposal randomization change fairly that significant of for in enrollment The I got there were patient safety on which them study, the based change the population change be enrolled criteria that database, the with the that comfortable FDA does so under the in isn't powering

Laura Chico

follow-up And helpful. I very That's guess question maybe one then.

to looking that data you mentioned ahead Phase out of I Just study. longer-term the the

to I around and think bit that was one some to are the be results. put thing These context a maybe X-year endpoints. little natural we've X- history going struggled

to be little to could coming context that using in certain results you to population are anticipated put or we point out if criteria a should wondering around Just the help these that come months here? metrics

Omar Khwaja

Yes absolutely.

essentially of are think natural I helpful are sources history. which So, data two there for

treatment other well So, one as are approaches. arms arms the as the control looking at of therapeutic

onset those four for three other think, treatments. three-year or initial data. helpful out types dopaminergic For studies brain the And formulations of to have data example going are context are deep XXXX be the of from for that setting to that I long-term collected years stimulation

second our but life and and progression assessments the not looking metrics natural disease quality that such primary other patient measures history and of more functioning. impact The Parkinson's or particularly UPDRS, diary at in as of just outcome cohorts

disease for and daily of modified other the activities example, Yahr example comorbidities So, living the UPDRS-II captured for disease falls. stage by for Hoehn example global and

So which give think metro, will the sets, XXXX at think are in looking history out I be data to that the helpful to context data. I natural

Laura Chico

much very Thanks guys.

Omar Khwaja

lot. Thanks a

Operator

Thank you.

next Duncan the Charles comes line from of Our Cantor with Fitzgerald. question

open. Your line is now

Charles Duncan

took you enroll to year. better the you congrats not that progress, one information I Or partnering drivers the to we is think one the two that questions there team If you. regarding the change as couple that was to you you of Thank is especially had there and able I to a any to Are new a a operational ask one? RESTORE-X? last look think, were Hi, mentioned more year wanted do RESTORE-X agency. change. of than you at driver great Or to anticipated? Andre the -- on patients in information?

Andre Turenne

Yeah. Thanks the question. for

likely last increase our the on were get of safety the program. we have data to into in with sham adding we able to from to get will one for powering to patients map sites, discussion to looking two what Neurocrine, one guided XXX patients right and of as the out a chance year, with think some And one. chance I a were the versus and benefit from of versus the level So we three surgery to exposure a with XX And we enrolling partner at statistically one some two get and we now trial. proposition -- one the of the

like to the a there study this. was justify us safety only enrollment, a to full for can one one led review one as a of two that not from a the much positive of sticking a between of one that exposure perspective that plan continued was So it the and the be statistical to cost the to one to with -- compare and but

Charles Duncan

to that? And positive you be That you data? think of see Could seems a terms how moving time to And real it in lines quicker do forward. makes perhaps sense. about

Andre Turenne

Yeah.

of out we're what further data. enter the discussed reducing a partner that to are facilitate of may study to an to also the randomization change would more decision in be the to the update getting to And bit to get completing that here. going burdensome as Omar we our So and on anticipate That's referred the site and scheme the little be of patient us even going study. able level. the But in the as more to assessments we on once investigators the new with we map provide give profile the yes implementation information some at impact further

Charles Duncan

a And you at to guideposts think RESTORE-X any RESTORE-X? kicking to RESTORE-X wondering Andre timing. done agency. steps least guess, analysis discussions recently is seems provide last off question regarding the rate-limiting about can with It additional my you've RESTORE-X? of are what on the the like And sizing rigorous and I I'm

Andre Turenne

Yeah. question. the Thanks for

partner to expect we have this endpoints. position study will So Neurocrine to very a RESTORE-X Generally the the the in in at our terms size, of expect end start of speaking, we'll characteristics that and design with with year. we similar be

to we of going we getting protocol, look So aspect that it's that international until won't with we RESTORE-X to -- be finalize sites. more be include number similar. we will expect The beyond one specific we but quite do is to goes that a RESTORE-X

study be sites. to the study, intended has only a So whereas, global is RESTORE-X U.S.

Charles Duncan

is Probably right only RESTORE-X that U.S. sites. good now

and color added on the progress. update the appreciate So

Andre Turenne

Thank you.

Operator

Thank you.

H.C. line of Wainwright. from Chattopadhyay Our Debjit the comes with next question

line is Your now open.

Aaron Welch

Aaron This questions. the taking Thanks guys. for Debjit. is Hi, on for

quickly, real powering baseline can as ON assumptions exactly are placebo? the us you time So what the from and RESTORE-X tell expected for change

Andre Turenne

Thanks for Aaron. the Yes. question,

to is powered hour be to placebo. or -- be study powered statistical sized well the or significance So is an showing for more against at

we So ended our up statistical that's how analyses. running

we're for significant a registrational X:X shown that's patients be we based statistically the that results on XX meaningful. and setting. going analyses pivotal and study the to what that as based prior in the study So clinically on with randomization something that's the looking obviously a we've with open-label And done achieved

Aaron Welch

a then second quick Okay. And question.

at looking may Caudate and Cortical much lowering. looks knockdown like Huntington data data, Neuron at putamen not preclinical HTT of of So -- it as a the problem

in So too as are lower striatum wild-type to Or which in a the there regions? critical is the the number concerns there protein Huntington's Huntington below lowering unintended... trying those you're about much

Andre Turenne

your question. Yes, thanks for

question. Omar, So this if you address can

Omar Khwaja

of think and where And necessary a I get the it's tissue XXX% where is to majority but primarily reduction been mutant the mean, the dose-efficacy mean of question. of done efficacy think has unlikely any wild-type in is I been I is the challenge with and what therapy predict efficacy moving a I target. that that preclinical the overall striatum The it's that -- data would being models transgenic therapeutic field I huntingtin a understand mouse of has think interest. clinical is region. of we cortical benefit. is mean sort little that's a Yes, particular try bit modality, any to reaching of bit the it's a great anchored. gene degree knockdown with in I brain

the broad I the where are XX% as in anchored in But to protein currently levels in we're reduction studies in would definitively mutant not doses think in efficacy reductions aiming it's cortex that striatum, multiple around for on of huntingtin the as regions the about get cortical give XX%. of at ballpark reduction animals. based transgenic which

Aaron Welch

Okay, Thank you helpful. great. That was guys. very

Andre Turenne

Thank you.

Operator

line next Jeff Our from Morgan of Hung Stanley. question the with comes

Your open. now is line

Hannah Latimer

Hi. This for is Hannah Jeff. on

Phase what of then it? the And do to in running would do study you be I study? what You're included -- IND? then expect Thanks. begin you Huntington's the the remains observational ahead to And outstanding you need expect when

Andre Turenne

Yes, thank you. Omar?

Omar Khwaja

the studies study we are for question. still IND of And guided thanks we are out which our coming filing, lot to GLP have bioanalytics the Yes, call, weeks. IND-enabling. -- running a last from are the in as our The on for we which XX

multiple And but the So number brain that's bioanalytics of of vector and samples. increased tissues in also genomes, regions. mRNA at microRNA itself an the including we're looking number a and also protein then from

the at that and really reviewing moment, going analyzing data it. So and we're through it

IND. lies not The is timing on the that's observational of this IND. the of and point between the study gated piece that sort time So the

set in coming is first by now active midyear anticipate being that that up that. we patients study and so And into with active

Andre Turenne

about observational participate do the we to or for not that as would be limiting. patients point, to maybe disease to expect to similar able not Omar expect severity, a therapeutics, run dependent, It's We just the to – add clinical of our that so that to in the we have said, study. maybe rate be the trial eligible therapeutics. – patients also in participate to it's not for of expect that the patients so last They're ones targeted in would study quite -- study we be but

Hannah Latimer

you. Thank Great.

Andre Turenne

you. Thank

Operator

Thank you.

Jim Birchenough from Our line Fargo. comes with next the of Wells question

now Your line open. is

Yanan Zhu

Yanan is Hi. Thanks for for Jim. taking dialing the in questions. This

on for the first time question follow-up So the to powering. was ON What earlier modeling? just about placebo arms the used assumption in

Andre Turenne

Yep. Yanan for the Thanks question.

placebo scenarios therapy point there's – mapped trials in against of year. prior a one at prior including So has range that at were seen the gene in time effect trials, been a the what similar

some and scenarios So of the the was to around to review right get based modeling on powering. them these

is a As our we've shared range in from placebo against a of effect a hour studies. hour primary to the of good previously, has endpoint of range which the an fraction ON range an time,

this? also our you modeling, appropriate bar. that hour So of plus to to the incorporate scenarios we get if effect Omar, add an to in to want go placebo to

Omar Khwaja

No.

I think that's right.

So the potential of arm true a then potential effect. necessary and we for size sample on outcomes simulations us decide capture to made assumptions would range placebo run that in range help be on that placebo to final the effect the the in

Yanan Zhu

you endpoint, you it. Got finalized out have I that? is identical? of later. you optionality on of kind helpful. design we know of RESTORE-X RESTORE-X RESTORE-X a previously on could of having update endpoint I so primary sense read be already But on on optionality Very will but terms – Could RESTORE-X had you and that yet and primary some the not and unblended, communicate be is to RESTORE-X in the sure. thoughts whether thought And mentioned get will before your – some you trial

Omar Khwaja

with top lock line data the and before so Yeah. RESTORE-X I to database need on will mean, that situation complete be they that finalize starts still staff RESTORE-X.

remains. So optionality that

as sites as will and a RESTORE-X Andre said will earlier think the be design with in ex-U.S. size sample main being number difference similar incorporate well. that RESTORE-X of substantially it I to

Yanan Zhu

competition Any when both the they're between two were the trials enrollment running? in potential they it. U.S. Got of for

Omar Khwaja

Yeah. It's a great question.

we'll recruit operationally. that, priority recruitment other one to-date also that In words sites study making activate able how sure for based anticipating has other. we're of I And cannibalizing handle we're RESTORE-X the the able seeing not sites recruitment we're that number and this before patients to on risk would into a RESTORE-X. of that are think there to be

Yanan Zhu

the very it. Got taking Thank you for much questions.

Andre Turenne

you. Thank

Operator

Thank you.

question of line Our the from with comes Oppenheimer. next Jay Olson

Your is now open. line

Silvan Tuerkcan

Silvan Tuerkcan Thanks RESTORE-X about regional Could on Hi. some RESTORE-X congrats the – RESTORE-X? on just for you're looking my management for questions you designing that Jay taking This at changes versus is and in Olson. quarter. when talk disease

Omar Khwaja

Yeah.

things mean, care one for of I the the standard geographies. that account across RESTORE-X in will variations So, for design be that go of in will

that One of brain availability the drivers stimulation. big the of is deep of

at of And least so that management part there separation so deep looking ex-U.S. what complete isn't we're RESTORE-X for the of in of for stimulation brain majority care, availability sites are countries remains where the a of patients.

that's to that. going an of So, be important part

going as countries Europe anticipating other we're and an Japan where remains countries at and option deep brain for really stimulation So, we where patients. look to

Silvan Tuerkcan

this And preclinical disease sets what at? be IND present year useful maybe publish for specifically that tell still filing, terms data us All look generating your right. Huntington's or us that maybe of may could in could is Great. you you left? you're for to what And

Omar Khwaja

absolutely. Yes

the the the GLP studies really phase moment to of that been large we're XX samples the during from bio-analytics taken So, up weeks. of have at in number completing analyzing

a significant analyzing of significant as regions. animals and we're as brain that of well So, a tissues number it's number

So, the the where predominantly of activity is IND sort team's really filing. -- that's the on for

on We that. well the as and now anticipate advanced at X a are for on right Phase time, would non-human team the and study stems appropriate focus activity now are observational the Phase long-term as lot is preparations for which The the predominant so of very second X. in patient our GLP an but the data our primate readiness presenting IND a from dosing studies preparation there's

Silvan Tuerkcan

so you Thank Great. much.

Andre Turenne

you. Thank

Operator

you. Thank

line comes Skorney next of the Baird. with Our Brian from question

open. line Your now is

Unidentified Analyst

questions. is so taking SODX our this the in on dialing have brief program. Brian. We for just one you Jack Hi, Thank for one much really

develop it's I program? just you moving know think plans could partner forward? you'd was to wondering now to forward indicated you Thank that about previously talk if internally you. preclinical you going still I moving or looking you are that there. are that your but partner had to that look I

Andre Turenne

Yes, thanks for Jack. question the

discussions and development efforts both So, discussions are corporate certain partnering but in we the of in assets. criteria prioritizing our efforts in broader parties that's about our other in and with ALS been potentially our SODX, mix -- of to We've -- inbound the been on the the on also effort. about

But focus towards SODX of HD on discussion I able to forms the some SODX said, level it to potentially leveraging have to ALS. of have learning broader what and on Like resources the with SODX, low to continue we potential apply activity IND other as to we be from continue include our effort partners. we've would shifted than advancing some are

Unidentified Analyst

much. Awesome. Thank you so

Andre Turenne

you. Thank

Operator

question-and-answer Thank now back turn you. to closing for Andre This concludes today's remarks. would session. I like to the Turenne call

Andre Turenne

Perfect.

today you we Thank next look on to everyone thank forward call opportunity So, for joining the update have our I to you and our progress. you.

Operator

for participating. Ladies and gentlemen, Thank this concludes call. you today's conference

may You now disconnect.

Voyager Therapeutics (VYGR) 3 Mar 202019 Q4 Earnings call transcript